Surgical Mortality Risk Scores in Transcatheter Aortic Valve Implantation: Is Their Early Predictive Value Still Strong? DOI Creative Commons
Fortunato Iacovelli, Francesco Loizzi, Alessandro Cafaro

et al.

Journal of Cardiovascular Development and Disease, Journal Year: 2023, Volume and Issue: 10(6), P. 244 - 244

Published: May 31, 2023

Surgical mortality risk scores, even if not properly designed and rarely tested in the transcatheter aortic valve implantation (TAVI) setting, still guide heart team managing significant stenosis.After splitting 1763 consecutive patients retrospectively based on their thresholds, composite endpoint early safety (ES) was adjudicated according to Valve Academic Research Consortium (VARC)-2 -3 consensus documents.ES incidence higher VARC-2 rather than VARC-3 defined. Despite only showing ES had significantly lower absolute values of all three main these last failed foresee both intermediate-risk patients. The receiver operating characteristic analysis also showed a correlation, but with poor diagnostic accuracy, among scores ES; moreover, absence low-osmolar contrast media administration were identified as independent predictors 1-year ES, respectively. Finally, single complication included definition could affect mortality.Currently, most used do have adequate accuracy predicting after TAVI. VARC-2, instead VARC-3, is an predictor mortality.

Language: Английский

Transcatheter Aortic Valve Replacement for Pure Native Aortic Valve Regurgitation DOI Creative Commons
Enrico Poletti, Ole De Backer, Andrea Scotti

et al.

КАРДИОЛОГИЯ УЗБЕКИСТАНА, Journal Year: 2023, Volume and Issue: 16(16), P. 1974 - 1985

Published: Aug. 1, 2023

Language: Английский

Citations

33
Evolut PRO and SAPIEN ULTRA Performance in Small Aortic Annuli DOI Creative Commons
Andrea Scotti, Matteo Sturla, Giuliano Costa

et al.

КАРДИОЛОГИЯ УЗБЕКИСТАНА, Journal Year: 2024, Volume and Issue: 17(5), P. 681 - 692

Published: March 1, 2024

Language: Английский

Citations

13
Comparison of outcomes of self-expanding versus balloon-expandable valves for transcatheter aortic valve replacement: a meta-analysis of randomized and propensity-matched studies DOI Creative Commons

Baiqiang Wang,

Zeyuan Mei,

Xiao Ge

et al.

BMC Cardiovascular Disorders, Journal Year: 2023, Volume and Issue: 23(1)

Published: July 31, 2023

The postoperative outcomes of transcatheter aortic valve replacement (TAVR) with the new generation self-expanding valves (SEV) and balloon-expandable (BEV) remain uncertain.

Language: Английский

Citations

21
Temporal Trends and Contemporary Outcomes After Transcatheter Aortic Valve Replacement With Evolut PRO/PRO+ Self-Expanding Valves: Insights From the NEOPRO/NEOPRO-2 Registries DOI Open Access
Andrea Scotti, Sara Baggio, Matteo Pagnesi

et al.

Circulation Cardiovascular Interventions, Journal Year: 2023, Volume and Issue: 16(1)

Published: Jan. 1, 2023

Background: In recent years, transcatheter aortic valve replacement (TAVR) techniques and technology have continuously improved. Data regarding the impact of these advancements on outcomes in large real-world settings are still limited. The aim this study was to investigate temporal trends assess contemporary after TAVR with Evolut PRO/PRO+ supra-annular self-expanding valves. Methods: This included patients enrolled multicenter NEOPRO (A Multicenter Comparison Acurate NEO Versus PRO Transcatheter Heart Valves) NEOPRO-2 ACURATE NEO2 Valves 2) registries who underwent transfemoral PRO/PRO+. Procedural dates (August 2017 through November 2021) were stratified quartiles (Q) used outcomes. Predischarge, 30-day Valve Academic Research Consortium-3 defined, 1-year evaluated. Results: total, 1616 from 28 centers included. Over time, had lower Society Thoracic Surgeon-Predicted Risk Mortality score (Q1–4, 4.1% [2.8–6.3%], 3.7% [2.6–5.3%], 3.3% [2.4–4.9%], 2.9% [2.2–4.3%]; P <0.001) more moderate or heavy calcification 80%, 82%, 88%; =0.038). Overall technical success 94.1%, all-cause mortality 2.4% 10%, respectively. Throughout period, procedures associated higher rates device 81.2%, 82.2%, 82.0%, 88.0%; Cochran-Armitage =0.023) early safety 66.8%, 67.5%, 74.0%, 77.6%; <0.001), fewer permanent pacemaker implantations (Q1–4: 15.3%, 20.0%, 12.1%, 11.6%; residual mild greater paravalvular leaks 50.4%, 42.1%, 36.5%, 35.8%; <0.001). Conclusions: is safe effective. Despite treatment heavier calcified anatomies, procedural improving over time less need for implantation significant leaks.

Language: Английский

Citations

17
Predictors, clinical impact, and management strategies for conduction abnormalities after transcatheter aortic valve replacement: an updated review DOI Creative Commons

Qingyun Yu,

Qingan Fu,

Yunlei Xia

et al.

Frontiers in Cardiovascular Medicine, Journal Year: 2024, Volume and Issue: 11

Published: April 8, 2024

Transcatheter aortic valve replacement (TAVR) has increasingly become a safe, feasible, and widely accepted alternative surgical treatment for patients with severe symptomatic stenosis. However, the incidence of conduction abnormalities associated TAVR, including left bundle branch block (LBBB) high-degree atrioventricular (HAVB), remains high is often correlated risk factors such as severity valvular calcification, preexisting conditions in patients, procedural factors. The existing research results on impact post-TAVR permanent pacemaker (PPM) requirements prognosis, all-cause mortality rehospitalization, remain contradictory, varied management strategies system diseases across different institutions. This review integrates latest field, offering comprehensive discussion mechanisms, factors, consequences, abnormalities. study provides insights into optimizing patient prognosis explores potential novel strategies, pacing, to minimize adverse clinical outcomes.

Language: Английский

Citations

5
Cusp overlap versus standard three-cusp technique for self-expanding Evolut transcatheter aortic valves DOI
Hendrik Wienemann, Oliver Maier, Martin K. Beyer

et al.

EuroIntervention, Journal Year: 2023, Volume and Issue: 19(2), P. e176 - e187

Published: June 1, 2023

Reducing rates of permanent pacemaker implantation (PPI) after transcatheter aortic valve (TAVI) is important for achieving the best procedural outcomes. The cusp overlap technique (COT) implements steps including an angulation right and left coronary to mitigate this complication.

Language: Английский

Citations

12
Prosthesis Tailoring for Patients Undergoing Transcatheter Aortic Valve Implantation DOI Open Access
Pier Pasquale Leone, Andrea Scotti, Edwin Ho

et al.

Journal of Clinical Medicine, Journal Year: 2023, Volume and Issue: 12(1), P. 338 - 338

Published: Jan. 1, 2023

Transcatheter aortic valve implantation (TAVI) has risen over the past 20 years as a safe and effective alternative to surgical replacement for treatment of severe stenosis, is now well-established recommended option in suitable patients irrespective predicted risk mortality after surgery. Studies numerous devices, either newly developed or reiterations previous prostheses, have been accruing. We hereby review TAVI with focus on commercially available options, aim present guide prosthesis tailoring according patient-related anatomical clinical factors that may favor particular designs.

Language: Английский

Citations

11
Platform Selection for Patients Undergoing Transcatheter Aortic Valve Replacement: A Practical Approach DOI Open Access
Roberto Valvo, Antonio Popolo Rubbio, Antonio Sisinni

et al.

Catheterization and Cardiovascular Interventions, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 24, 2025

ABSTRACT Transfemoral transcatheter aortic valve Replacement (TAVR) has become the standard therapy for patients with severe stenosis in over 75 years old Europe or 65 United States, regardless of surgical risk. Furthermore, iterations existing valves (TAVs), as well devices novel concepts, have provided substantial improvements respect to limitations previous‐generation devices. Hence, treatment a broader spectrum feasible, and sophisticated selection appropriate TAV tailored patients' anatomy comorbidities is now possible. Anatomy, patient characteristics, operator experience must all inform proper device selection. This review describes features performance current generation TAVs aim providing practical approach clinicians when selecting specific patient.

Language: Английский

Citations

0
TAVR and Strokes DOI Creative Commons
Kush Patel, Andreas Baumbach

JACC Asia, Journal Year: 2025, Volume and Issue: 5(2), P. 270 - 272

Published: Feb. 1, 2025

Language: Английский

Citations

0
Balloon-expandable SAPIEN 3 Ultra valve in intermediate sizing zones: insights from the OPERA-TAVI registry DOI
Giuliano Costa, Thomas Pilgrim, Francesco Saia

et al.

EuroIntervention, Journal Year: 2025, Volume and Issue: 21(5), P. e282 - e284

Published: Feb. 24, 2025

Language: Английский

Citations

0